Anti-Sclerostin antibody - Aminoterminal end (ab63097)
- Product nameAnti-Sclerostin antibody - Aminoterminal endSee all Sclerostin primary antibodies ...
- DescriptionRabbit polyclonal to Sclerostin - Aminoterminal end
- Tested applicationsWB, ELISA, IHC-P more details
- Species reactivityReacts with: Mouse, Sheep, Human
KLH conjugated synthetic peptide selected from the N terminal region of human Sclerostin.
- Positive control
- WB: Mouse liver tissue lysate IHC-P: Human breast carcinoma tissue
- Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.09% Sodium Azide
- Concentration information loading...
- PurityProtein A purified
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab63097 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/50 - 1/100. Detects a band of approximately 24 kDa (predicted molecular weight: 24 kDa).|
|IHC-P||IHC-P: 1/10 - 1/50.|
- FunctionNegative regulator of bone growth.
- Tissue specificityWidely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteeoblasts differentiated for 21 days.
- Involvement in diseaseDefects in SOST are the cause of sclerosteosis (SOST) [MIM:269500]; also known as cortical hyperostosis with syndactyly. SOST is an autosomal recessive sclerosing bone dysplasia characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients.
Note=A 52 kb deletion downstream of SOST results in SOST transcription suppression and is a cause of van Buchem disease (VBCH) [MIM:239100]; also known as hyperostosis corticalis generalisata. VBCH is an autosomal recessive sclerosing bone dysplasia characterized by endosteal hyperostosis of the mandible, skull, ribs, clavicles, and diaphyses of the long bones. Affected patients present a symmetrically increased thickness of bones, most frequently found as an enlarged jawbone, but also an enlargement of the skull, ribs, diaphysis of long bones, as well as tubular bones of hands and feet. The clinical consequence of increased thickness of the skull include facial nerve palsy causing hearing loss, visual problems, neurological pain, and, very rarely, blindness as a consequence of optic atrophy. Serum alkaline phosphatase levels are elevated.
- Sequence similaritiesBelongs to the sclerostin family.
Contains 1 CTCK (C-terminal cystine knot-like) domain.
- Cellular localizationSecreted.
- BEER antibody
- CDD antibody
- Cortical hyperostosis with syndactyly antibody
- Sclerosteosis antibody
- Sclerostin antibody
- SOST antibody
- SOST_HUMAN antibody
- UNQ2976/PRO7455/PRO7476 antibody
- VBCH antibody
Anti-Sclerostin antibody - Aminoterminal end images
Anti-Sclerostin antibody - Aminoterminal end (ab63097) at 1/60 dilution + mouse liver tissue lysates at 35 µg
Predicted band size : 24 kDa
Observed band size : 24 kDa
Additional bands at : 55 kDa. We are unsure as to the identity of these extra bands.
Immunohistochemical analysis of sclerostin expression in paraffin embedded formalin fixed human breast carcinoma tissue section using 1/10 ab63097, followed by HRP conjugated secondary antibody step and DAB staining.
References for Anti-Sclerostin antibody - Aminoterminal end (ab63097)
This product has been referenced in:
- Cohen-Kfir E et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152:4514-24 (2011). Mouse . Read more (PubMed: 21952235) »
- Mardaryev AN et al. Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle. FASEB J 24:3869-81 (2010). WB ; Mouse . Read more (PubMed: 20522784) »